Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Given Average Recommendation of “Hold” by Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has been assigned a consensus recommendation of “Hold” from the twenty-two analysts that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $113.45.

ZBH has been the subject of several recent analyst reports. BTIG Research restated a “buy” rating on shares of Zimmer Biomet in a research note on Monday, April 14th. Wells Fargo & Company lowered their target price on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 6th. Raymond James lowered their target price on Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. Royal Bank of Canada lowered their target price on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th. Finally, Robert W. Baird lowered their target price on Zimmer Biomet from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Tuesday, May 6th.

Zimmer Biomet Trading Up 0.1%

NYSE:ZBH opened at $96.78 on Friday. The business’s 50-day moving average is $103.41 and its two-hundred day moving average is $105.87. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet has a 12 month low of $89.92 and a 12 month high of $121.30. The firm has a market capitalization of $19.15 billion, a PE ratio of 21.75, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The company had revenue of $1.91 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same period last year, the company posted $1.94 earnings per share. The firm’s revenue was up 1.1% compared to the same quarter last year. Research analysts predict that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 0.99%. Zimmer Biomet’s payout ratio is currently 21.24%.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. The trade was a 14.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 1.39% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently bought and sold shares of ZBH. CKW Financial Group raised its holdings in shares of Zimmer Biomet by 11.7% during the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after buying an additional 100 shares during the last quarter. Romano Brothers AND Company raised its holdings in shares of Zimmer Biomet by 1.1% during the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after buying an additional 102 shares during the last quarter. Dorsey & Whitney Trust CO LLC raised its holdings in shares of Zimmer Biomet by 2.3% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider’s stock valued at $485,000 after buying an additional 102 shares during the last quarter. M&T Bank Corp raised its holdings in shares of Zimmer Biomet by 0.4% during the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider’s stock valued at $2,834,000 after buying an additional 108 shares during the last quarter. Finally, MGO One Seven LLC raised its holdings in shares of Zimmer Biomet by 5.1% during the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider’s stock valued at $238,000 after buying an additional 110 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.